Cytokines and depression: The need for a new paradigm
- 21 January 2003
- journal article
- review article
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 17 (1), 119-124
- https://doi.org/10.1016/s0889-1591(02)00078-8
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapyMolecular Psychiatry, 2002
- Neurobehavioral Effects of Interferon-α in Cancer Patients Phenomenology and Paroxetine Responsiveness of Symptom DimensionsNeuropsychopharmacology, 2002
- Treatment with interferon-alpha (IFNα) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFNα-induced depressive and anxiety symptoms and immune activationMolecular Psychiatry, 2001
- Effects of Antidepressant Drugs on the Behavioral and Physiological Responses to Lipopolysaccharide (LPS) in RodentsNeuropsychopharmacology, 2001
- Paroxetine for the Prevention of Depression Induced by High-Dose Interferon AlfaNew England Journal of Medicine, 2001
- Clinical and Physiological Consequences of Rapid Tryptophan DepletionNeuropsychopharmacology, 2000
- The Corticosteroid Receptor Hypothesis of DepressionNeuropsychopharmacology, 2000
- Olfactory Bulbectomy Provokes a Suppression of Interleukin-1β and Tumour Necrosis Factor-α Production in Response to an in vivo Challenge with Lipopolysaccharide: Effect of Chronic Desipramine TreatmentNeuroimmunomodulation, 1999
- The Proinflammatory Cytokine, Interleukin-1 , Reduces Glucocorticoid Receptor Translocation and FunctionEndocrinology, 1999
- Cytokines and depression: fortuitous or causative association?Molecular Psychiatry, 1999